Apart from the links with glioma grade and genetic mutations, survival analysis based on GEPIA (n = 676) and CGGA (n = 404) data enabled the prognostic evaluation for the clinical value of the HDAC family. This evidence concerns the gene HDAC9 and central nervous system cancer.